The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
Trial details
- Registry ID
- NCT04136366
- Phase
- Phase 3
Drug identity has not yet been verified against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative VitreoretinopathyNCT04136366 | ALDX | Phase 3 | Completed | 2022-06-14Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |